首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
医学
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
admin
2013-11-30
32
问题
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea; the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy , diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. " We’ ve been too rigid in not making life-saving drugs available to people who otherwise face certain death," says Representative Henry Wax-man, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’ s true of AIDS, but it’ s also true of cancer and other life-threatening diseases. "
For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story; a crisis—AIDS—helped crystallize an informal coalition for reform.
AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Drug Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs, those that show new promise in treating serious or life—threatening diseases—had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it proposed died in Congress. Complaints were compounded by growing concern that "if we didn’ t streamline policies, red tape would be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
Young was a key figure in the overhaul of the FDA’ s policies. A pioneer in biotechnology and a former dean of the University of Rochester’ s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology—whose promise he had seen in his own gene-cloning lab and to get experimental medicines to desperately ill people more quickly. He had seen people die waiting for new medicines because " they were in the wrong place at the wrong time," he said. That is now changing.
During his tenure of office as head of the FDA, Frank E. Young______.
选项
A、had a bitter argument with his colleagues over the overhaul of drug-approval policies
B、played a leading role in reconstructing the FDA’ s policies
C、made some efforts to overhaul drug-approval policies, but failed
D、met many difficulties in releasing breakthrough drugs to the desperately ill patients
答案
B
解析
最后一段第一句指出“Young was a key figure in the overhaul of the FDA’s policies”,即Young在FDA的政策修订方面是一个重要人物,选项B正确。
转载请注明原文地址:https://kaotiyun.com/show/ftU3777K
本试题收录于:
医学博士外语题库考研分类
0
医学博士外语
考研
相关试题推荐
下面哪一项不符合干扰素治疗乙肝炎的指征
Severalclassesofbittercitruscompoundhavelookedpromisingasanticanceragentsinlaboratorytests.Anewstudyindicates
Cultureshockmightbecalledanoccupationaldiseaseofpeoplewhohavebeensuddenlytransplantedabroad.Likemostailments,
Hemadeacareerofimitatingfamouspeoplefornightclubaudiences.
I’mintheunusualpositionofbeingbothacomputerscientistandaprofessionalmusician.Onthecomputerside,I’mbestkno
Tostudythedistributionofdiseasewithinanarea,itisusefultoplotthecasesonamap.
A、Alicealwaysperformsatthesamelevel.B、Alicealwaysperformswonderfully.C、Aliceperformedpoorlyyesterday.D、Aliceperf
FamedsingerSteveWondercan’tseehisfansdancingathisconcerts.Hecan’tseethehandsofhisaudienceastheyapplaudw
FamedsingerSteveWondercan’tseehisfansdancingathisconcerts.Hecan’tseethehandsofhisaudienceastheyapplaudw
Friedfoodshavelongbeenfrownedupon.Nevertheless,theskilletisaboutourhandiestandmostusefulpieceofkitchenequipm
随机试题
下面程序的运行结果是()main(){inty=5,x=14;y=((x=3*y,x+6),x-1);printf("x=%d,y=%d",x,y);}
巴纳德指出,下属对组织命令的反应可能有三种形式,这不包括()
不属于初级结合型胆汁酸的是
A.中极B.关元C.气海D.天枢常用以诊断小肠病的腧穴是
A.结节性甲状腺肿B.甲亢C.慢性淋巴细胞性甲状腺炎D.甲状腺腺瘤E.甲状腺癌与生理因素及缺碘有关
男,40岁。干农活时刺伤右足10天,伤后未就医,张口困难2天,颈项紧,频繁抽搐,呼吸道分泌物较多,有窒息的危险,为保持呼吸道的通畅。最有效的措施是
据中国B2B研究中心相关调查数据显示,截止到2009年6月,我国规模以上电子商务网站总量已经达12282家。其中,B2B电子商务服务企业有5320家,B2C、C2C与其他非主流模式企业达6962家,特别是自进入2008年来,呈现出高速增长、乃至井喷之势。
一项工程交由甲、乙两个工程队负责,甲队单独干了4天后,乙队加入和甲队一起干,又过了5天完成了全部工程的。两个队又干了9天正好完成了全部工程的。此时甲队另有任务撤走,乙队独自完成了剩下的工程。这项工程从开始到完工总共用了()天。
抗日根据地的教育方针政策包括______、______、______。
设随机变量X在区间(0,1)上服从均匀分布,当X取到x(0<x<1)时,随机变量Y等可能地在(x,1)上取值。试求:P{X+Y>1}。
最新回复
(
0
)